Protein key to diagnosing, treating some cancers

By The Science Advisory Board staff writers

August 11, 2022 -- The pathway of a certain protein could lead to early diagnosis and targeted treatment of several cancers and brain disorders, according to Queen’s University Belfast in Northern Ireland researchers.

The molecular mechanisms of epithelial to mesenchymal transition (EMT) are essential for the migration of newborn neurons during brain development, but a defect in this process can also cause cancer metastasis. This discovery has ramifications for understanding cancer metastasis and brain development and could lead to earlier diagnosis and better treatments, according to the authors (Nature Cell Biology, August 8, 2022).

EMT enables cell migration and is vital for early development processes including brain development as well as for wound healing later in life. However, it's also used by cancer cells for metastasis. The scientists identified the protein ZNF827 as a critical regulator of EMT. The protein orchestrated a large-scale remodeling of the splicing landscape by recruiting HDAC1 for epigenetic modulation of distinct genomic loci. This slowed RNA polymerase II progression and altered the splicing of genes encoding key EMT regulators in cis.

The findings reveal an "unprecedented" complexity of crosstalk between epigenetic landscape and splicing program in governing EMT and identifies ZNF827 as a master regulator coupling these processes during EMT in brain development and breast cancer metastasis.

This discovery opens new opportunities for a therapeutic intervention against cancer and a better understanding of neurodevelopmental disorders involving defects in brain development, the authors said.

Copyright © 2022

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.